Martin Dietrich, MD, PhD

Medical oncologists discuss the overall research landscape in advanced EGFR-mutant NSCLC, highlighting exciting trials and emerging data in the evolving treatment space.

Martin Dietrich, MD, PhD, shares expert perspectives on recent data from TROPION-Lung05 and HERTHENA-Lung01 in advanced EGFR-mutant NSCLC.

Wade T. Iams, MD, provides clinical insights on proactive management strategies for patients receiving amivantamab for advanced EGFR-mutant NSCLC.

Focusing on treatment practices for patients with advanced EGFR-mutant NSCLC, Martin Dietrich, MD, PhD, discusses how the availability of subcutaneous amivantamab can potentially address current treatment barriers.

Wade T. Iams, MD, outlines insights gleaned from recently presented data from the PALOMA-3 trial in advanced EGFR-mutant non–small cell lung cancer.

Martin Dietrich, MD, PhD, discusses the secondary analysis from MARIPOSA evaluating first-line amivantamab plus lazertinib in patients with advanced EGFR-mutant NSCLC.

Following the 2024 ASCO Annual Meeting, medical oncologists share insights on how the availability of the FLAURA2 treatment regimen has impacted the treatment of patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC).

The panelist summarizes the major findings from MARIPOSA-2 and their conclusions about amivantamab regimens improving outcomes in osimertinib-resistant NSCLC.

This segment summarizes the pivotal efficacy and safety outcomes from the MARIPOSA-2 trial of amivantamab-based regimens in osimertinib-resistant EGFR-mutant NSCLC. It explores the clinical implications of these data and potential future research directions.

A comprehensive look at the safety data from the MARIPOSA-2 trial, including rates of adverse events, toxicities, and treatment modifications across the three regimens. Specific details are provided on adverse event types and grades by the treatment arm.

This segment focuses on the key efficacy data on progression-free survival, response rates, and duration of response from MARIPOSA-2.

In this segment the panelist reviews the baseline patient and disease characteristics across the three treatment arms in MARIPOSA-2.

A commentary on key takeaways from TROPiCS-02, remaining questions and unmet needs in the field, and the clinical implications of using SG and other Trop-2–directed ADCs in patients with HR+/HER2- mBC.

Drs Dietrich, Tolaney, and Vidal comment on PFS subgroup analyses, response rates, and common adverse events (AEs) observed in the TROPiCS-02 trial.

Experts discuss progression-free survival (PFS) and overall survival (OS) data from the TROPiCS-02 trial on SG versus treatment of physician’s choice.

Dr Tolaney discusses the TROPiCS-02 study design and comments on the key baseline characteristics of the patients with HR+/HER2- mBC who were enrolled in the trial.

Dr Vidal elaborates on the role of trophoblast cell-surface antigen 2 (Trop-2) in metastatic breast cancer and discusses the rationale for using Trop-2–directed antibody-drug conjugates (ADCs), including sacituzumab govitecan (SG), in patients with the disease.

Sara Tolaney, MD, MPH introduces the 2022 Journal of Clinical Oncology preprint publication, “Sacituzumab Govitecan in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer” and invites Martin Dietrich, MD, PhD and Gregory Vidal, MD, PhD to comment on the typical patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (mBC) who they see in their clinical practice.

Expert oncologists look toward future utilization of circulating tumor DNA testing and consider how the field of oncology may evolve.

Shared insight on how circulating tumor DNA may be used in real-world clinical practice to improve the value of cancer care.

Focusing broadly on breast cancer, expert oncologists detail how ctDNA may impact patient monitoring and treatment decisions moving forward.

Moving on to the second patient scenario, panelists elucidate the value of ctDNA in patients with triple-negative breast cancer.

In the context of clinical trial data and personal experience, experts weigh the value of circulating tumor DNA as a tool in cancer care.

Experts share their perspective on clinical trial data driving the use of circulating tumor DNA in various settings of cancer care.

Focusing on breast cancer, lung cancer, and GI cancers respectively, expert oncologists review the utility of circulating tumor DNA assays.

Expert panelists elucidate the mechanisms of ctDNA and MRD testing, providing a broad perspective on how they are used in cancer care.

Shared insight on the potential roles of ctDNA and MRD testing in the monitoring and treatment of patients with colorectal cancer.

Centering discussion on a patient scenario of stage II colorectal cancer, expert oncologists consider how ctDNA may inform use of adjuvant chemotherapy in this setting.